The data thus highly suggest that circulating tumor CSC–derived CD133+ CD326- EVs can be used as screening and diagnostic biomarkers for lung cancer and that patient clinical outcomes correlate with the concentration of CD133+ CD326- EVs (Brocco et al., 2019) (Table 2). Here, EPCAM is linked to lung carcinoma.